Biomarkers Beyond ALP to Monitor for Measuring PBC UDCA Response to Therapy and Disease Progression

Thank you Intercept for your support of this podcast episode.

Welcome to the CLDF GHAPP PBC Podcast Series! In this episode of our eight-part series, host Andrea Gossard, NP, is joined by Christina Hanson, FNP and CLDF GHAPP board member, to explore the evolving role of biomarkers in the diagnosis, monitoring, and personalized treatment of Primary Biliary Cholangitis (PBC). Together, they examine how clinicians are rethinking the utility of traditional markers such as alkaline phosphatase and bilirubin, and how newer data support the use of additional biomarkers—including ALT, AST, and GGT—for a more comprehensive picture of disease activity and therapeutic response. This discussion includes practical guidance on baseline evaluation with FibroScan, interpretation of liver stiffness measurements, and when to consider second-line therapies. Christina shares her clinical insights from real-world hepatology practice, emphasizing the importance of early intervention, individualized timelines for assessing treatment response, and the growing recognition that even small elevations in liver enzymes may signal a need for more aggressive care. This episode is a must-listen for hepatology providers and GI specialists who want to stay up to date with the latest evidence-based strategies in PBC management. Subscribe and follow along as we continue this educational journey throughout the full series.